Lazard Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Lazard Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,894	Closed	-$41K	–	2625
2023 Q1	$41K	Hold	9,894	–	–	﹤0.01%	1858
2022 Q4	$59K	Hold	9,894	–	–	﹤0.01%	1727
2022 Q3	$57K	Buy	+9,894	New	+$61.7K	﹤0.01%	1746

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Lazard Asset Management's CTIC Position: Q2 2023 in Review

Lazard Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 9,894 shares — an estimated $41K sold.

Lazard Asset Management first reported a position in CTIC in Q3 2022 and held it in 3 quarters. The position peaked at $59K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Lazard Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Lazard Asset Management sold 9,894 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $41K.
Lazard Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2022 and held it in 3 quarters.
Lazard Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $59K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Lazard Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.